Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Receivables - Net: 2022-2025

Historic Receivables - Net for Arcutis Biotherapeutics (ARQT) over the last 3 years, with Sep 2025 value amounting to $115.1 million.

  • Arcutis Biotherapeutics' Receivables - Net rose 91.48% to $115.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $115.1 million, marking a year-over-year increase of 91.48%. This contributed to the annual value of $73.1 million for FY2024, which is 183.12% up from last year.
  • According to the latest figures from Q3 2025, Arcutis Biotherapeutics' Receivables - Net is $115.1 million, which was up 7.90% from $106.7 million recorded in Q2 2025.
  • Arcutis Biotherapeutics' 5-year Receivables - Net high stood at $115.1 million for Q3 2025, and its period low was $2.4 million during Q3 2022.
  • Moreover, its 3-year median value for Receivables - Net was $43.4 million (2024), whereas its average is $54.2 million.
  • Data for Arcutis Biotherapeutics' Receivables - Net shows a peak YoY spiked of 698.72% (in 2023) over the last 5 years.
  • Quarterly analysis of 4 years shows Arcutis Biotherapeutics' Receivables - Net stood at $8.5 million in 2022, then spiked by 205.12% to $25.8 million in 2023, then soared by 183.12% to $73.1 million in 2024, then soared by 91.48% to $115.1 million in 2025.
  • Its Receivables - Net was $115.1 million in Q3 2025, compared to $106.7 million in Q2 2025 and $85.4 million in Q1 2025.